On June 9, Innovent Biologics fell 3.07% in regular trading, trading at 70.75 HKD/share, with trading volume of HKD 260 million. The stock has declined for multiple consecutive trading days following an 11%+ surge on May 29 when the company announced a USD 10.5 billion global strategic partnership with Pfizer.

On the news front, market concerns persist over whether the Pfizer transaction can secure required regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the U.S. COINS Act's potential restrictions on biotechnology have intensified uncertainty, continuing to suppress investor sentiment. Of the USD 10.5 billion total deal value, only the USD 650 million upfront payment is confirmed, while the remaining USD 9.85 billion in milestone payments depends on clinical, regulatory, and commercial milestones spanning 5-8 years.

Within the Biotechnology sector, broad-based weakness persists. Among individual stocks, Akeso down 3.58%, BeiGene down 1.96%, Remegen down 2.11%, SKB Bio down 0.63%, 3SBio down 1.51%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)